Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled budesonide for prevention of bronchopulmonary dysplasia in preterm infants
IRCT20230823059227N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bronchopulmonary dysplasia (BPD) comparing Budesonide nebulization with Placebo nebulization (2 arms). Primary endpoints: Bronchopulmonary dysplasia, Mortality rate and 7 more. Started Sep 2023; status: completed.
02
Drugs
budesonide
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on IRCT20230823059227N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230823059227N1.